Former Astra USA Chief Pleads Not Guilty
Lars Bildman, former chief executive of Astra USA, a subsidiary of theSwedish firm Astra, has entered a plea of not guilty in answer to US federal charges of stealing over $1 million from the company and allegedly using it to finance personal trips, prostitutes and home improvements (Marketletter March 24). Mr Bildman was fired last summer when allegations surfaced at Astra USA of sexual harassment of employees and the disappearance of company funds. He is also accused of attempting to hide his actions by destroying records.
Prosecutors suggest that Mr Bildman could face more than 10 years in prison and fines of hundreds of thousands of dollars if found guilty, reports the Wall Street Journal. Mr Bildman's trial is understood to be scheduled for June 23.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze